AIM Therapeutics advances asthma therapeutics program

    TORONTO, Feb. 4 /CNW/ - AIM Therapeutics Inc. ("AIM") is pleased to
announce that the company's asthma program has entered the next phase of
development towards the clinic. Based on positive results from recent efficacy
and dose-response studies, AIM has initiated the pre-clinical development
program for its lead Neutropel candidate, AIM-102, for the treatment of
    AIM has engaged CARBOGEN AMCIS AG for process development and cGMP
manufacture of AIM-102, with plans to complete its pre-clinical development
program for the treatment of asthma by the end of the third quarter of 2008.
    AIM is a privately held pharmaceutical company focused on developing
novel medical treatments for inflammatory and immune disorders. The company's
most advanced program is a breakthrough technology called Neutropel, which is
a non-toxic, non-steroidal therapeutic that can be given orally, by inhalation
or by injection.
    "The potential for AIM-102 to effectively treat asthma without
steroid-like side effects will significantly improve the lives of many people
who suffer from this debilitating disease" said Dr. Richard Timmer, AIM
President and CEO. "We are proud of our progress, and we look forward to
working with CARBOGEN AMCIS AG to advance the development of our asthma
    AIM will work closely with CARBOGEN AMCIS AG to develop and manufacture
cGMP material. The cGMP material will be used to support the pre-clinical
development program, as well as Phase I clinical studies for AIM's asthma
program. AIM has chosen to work with CARBOGEN AMCIS AGE because of their
excellent track record, attention to detail, and strong capabilities in both
process development and cGMP manufacturing for the pharmaceutical industry.
    For more information about AIM Therapeutics and any of its technologies
or development programs, please visit

    About AIM Therapeutics

    AIM Therapeutics Inc. is a privately held biotechnology company focused
on the development of peptide-based therapeutic candidates for the treatment
of asthma, cardiovascular disease, diabetes, spinal cord injury, and other
inflammatory and immune disorders. The Company's therapeutic candidates are
based on research from leading scientists at the University of Western Ontario
and the University of Calgary. AIM Therapeutics is pursuing the pre-clinical
validation and development of its lead candidates through a virtual business
model being managed by BioQuest Innovations Inc.


    CARBOGEN AMCIS AG is a leading service provider, offering a portfolio of
drug-development and commercialization services to the pharmaceutical and
biopharmaceutical industry at all stages of drug development. The integrated
services provide innovative chemistry solutions to support timely and safe
drug development allowing customers to make the best use of available

For further information:

For further information: Dr. Richard Timmer, President and CEO, AIM
Therapeutics Inc., MaRS Centre, Heritage Building, 101 College Street, Suite
335, Toronto, Ontario, M5G 1L7, (416) 673-8199,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890